公司表现 - Bicycle Therapeutics PLC Sponsored ADR (BCYC) 今年以来股价上涨11.8%，高于医疗行业平均5.8%的涨幅 [2] - 公司当前Zacks Rank评级为2 (Buy)，表明其盈利前景改善 [2] - 过去一个季度，BCYC全年盈利共识预期上调14.6%，反映分析师情绪转强 [2] - 同行业公司Twist Bioscience (TWST) 今年以来涨幅达26.1%，其当前年度EPS共识预期过去三个月上调2.6% [2][3] 行业地位 - 医疗行业在Zacks Sector Rank中排名第7，包含1040家公司 [1] - BCYC所属的医疗-生物医学和遗传学子行业包含501家公司，在Zacks Industry Rank中排名第88 [3] - 该子行业今年以来平均下跌4.1%，BCYC和TWST表现优于行业平均水平 [3] 投资建议 - 投资者应持续关注BCYC和TWST，因其可能保持强劲表现 [3]

公司表现 - Bicycle Therapeutics PLC Sponsored ADR (BCYC) 今年以来股价上涨28.1%，表现优于医疗行业平均6.2%的涨幅 [2] - 公司当前Zacks Rank为2（买入），显示其盈利前景改善 [1] - 过去一个季度，BCYC全年盈利的Zacks共识预期上调14.6%，反映分析师情绪改善 [2] 行业比较 - BCYC所属医疗-生物医学和遗传学行业包含503家公司，行业排名第80，行业平均下跌3.8% [3] - 对比公司Brookdale Senior Living (BKD) 属于医疗-养老院行业（2家公司），行业排名第16，行业平均上涨7.5% [3] - BKD今年以来上涨14.6%，过去三个月其全年EPS共识预期上调21.2%，同样获得Zacks Rank 2（买入）评级 [2][3] 行业概况 - 医疗板块包含1044只个股，当前Zacks Sector Rank排名第7 [1] - Zacks Sector Rank通过衡量板块内个股Zacks Rank的平均值来评估16个行业组的强度 [1]

Bicycle Therapeutics (BCYC) shares rallied 9.6% in the last trading session on May 23 after the company announced entering into a funding agreement with multiple institutional investors, new and existing, to issue and sell an aggregate of 25,933,706 American Depositary Shares (ADS) at $21.42 per share. Such impending transaction will be accomplished via a private investment in public equity (PIPE) financing.Please note that one ADS of Bicycle Therapeutics represents one ordinary share of the company.The com ...

Bicycle Therapeutics PLC Sponsored ADR (BCYC) closed the last trading session at $23.48, gaining 4.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $43.56 indicates an 85.5% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $11.61. While the lowest estimate of $30 indicates a 27.8% increase from the current price level, the mo ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bicycle Therapeutics PLC Sponsored ADR (BCYC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Bicycle Therapeutics PLC Sponsored ADR is a member of the Medical sector. This group includes 1047 individual stocks ...

Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and fol ...

Shares of Bicycle Therapeutics PLC Sponsored ADR (BCYC) have gained 8.1% over the past four weeks to close the last trading session at $24.58, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $43.56 indicates a potential upside of 77.2%.The average comprises nine short-term price targets ranging from a low of $30 to a high of $60, with a standard deviation of $11.61. While the lo ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, nominal value £0.01 per share* n/a The Nasdaq Stock Market LLC American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

现金及现金等价物 - Bicycle Therapeutics于2024年第一季度末现金及现金等价物为4.57亿美元，预计可支持至2026年[1] 研发费用 - 研发费用为3,490万美元，较去年同期增加270万美元，主要是由于BT8009开发的临床项目费用增加和人员相关费用增加[9] 总体运营费用 - 总体运营费用为5,124.6万美元，较去年同期增加1,547.1万美元[15]

文章核心观点 生物制药公司Bicycle Therapeutics宣布其三篇摘要被接受在2024年美国癌症研究协会（AACR）年会上以海报形式展示 [1] 海报展示详情 - 标题为“Bicycle Toxin Conjugates® for the treatment of solid tumors”的海报，将于4月9日下午1:30 PT/4:30 ET展示，摘要编号5807，主讲人/第一作者为Stephen Walsh博士 [2] - 标题为“Modulation of the natural killer cell immune response to tumor with a synthetic tumor - immune cell agonist, NK - TICA™”的海报，将于4月8日上午9 a.m. PT/12 p.m. ET展示，摘要编号1340，主讲人/第一作者为Fay Dufort博士 [2] - 标题为“Tumor - targeted activation of CD137 using Bicycles: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2 - expressing cancers”的海报，将于4月9日下午1:30 PT/4:30 ET展示，摘要编号5301，主讲人/第一作者为Johanna Lahdenranta博士 [2] - 海报展示结束后将在bicycletherapeutics.com的出版物板块提供 [2] 公司介绍 - Bicycle Therapeutics是临床阶段生物制药公司，开发名为Bicycle®分子的新型药物，用于现有疗法难以治疗的疾病 [3] - Bicycle分子是完全合成的短肽，与小分子支架结合形成两个环以稳定结构几何，能高亲和力和选择性结合靶点，是有吸引力的药物开发候选物 [3] - 公司正在评估BT8009、BT5528和BT7480在公司赞助的临床试验中的表现，还在开发Bicycle® Radio Conjugates（BRC™）用于放射性药物，并通过合作探索Bicycle®技术在肿瘤学以外疾病治疗中的应用 [3] 公司地址 - 公司总部位于英国剑桥，许多关键职能部门和领导团队成员位于美国马萨诸塞州剑桥，更多信息可访问bicycletherapeutics.com [4]